Propranolol Attenuates Surgical Stress–Induced Elevation of the Regulatory T Cell Response in Patients Undergoing Radical Mastectomy

Surgical stress and inflammatory response induce the release of catecholamines and PGs, which may be key factors in facilitating cancer recurrence through immunosuppression. Animal studies have suggested the efficacy of perioperative blockades of catecholamines and PGs in reducing immunosuppression. In this study, to our knowledge, we present the first report of the effects of perioperative propranolol and/or parecoxib on peripheral regulatory T cells (Tregs) in breast cancer patients. Patients were randomly assigned to control, propranolol, parecoxib, and propranolol plus parecoxib groups. We demonstrated that levels of circulating epinephrine, norepinephrine, and PGE2 increased in response to surgery. Meanwhile, peripheral FOXP3 mRNA level and Treg frequencies were elevated on postoperative day 7. Propranolol administration, rather than parecoxib, attenuated such elevation of Tregs, indicating the critical roles for catecholamines in surgery-induced promotion of Tregs. Besides, propranolol plus parecoxib treatment demonstrated no additive or synergistic effects. Furthermore, a study of Treg activity on CD4+ T cell responses to specific tumor Ags was performed in the control and propranolol groups. Propranolol abrogated the increased Treg activity and accompanying suppression of CD4+ T cell responses after surgery. Finally, we conducted ex vivo experiments on the effects of varying concentrations of epinephrine and/or propranolol on Treg proliferation over PBMCs from breast cancer patients, to provide further direct evidence strengthening our clinical observations. Epinephrine markedly promoted Treg proliferation, whereas propranolol prevented such enhancement effect. In conclusion, our study highlights beneficial roles for propranolol in inhibiting Treg responses in vivo and in vitro, and demonstrates that propranolol could alleviate surgical stress–induced elevation of Tregs in breast cancer patients.

[1]  S. Fisher,et al.  Norepinephrine and ANG II stimulate secretion of TGF-beta by neonatal rat cardiac fibroblasts in vitro. , 1995, The American journal of physiology.

[2]  D. Lysle,et al.  Severity, time, and beta-adrenergic receptor involvement in surgery-induced immune alterations. , 1998, The Journal of surgical research.

[3]  W. Sano,et al.  Changes in immune function following surgery for esophageal carcinoma. , 1999, Nutrition.

[4]  T. Kajiwara,et al.  Suppression of cellular immunity by surgical stress. , 2000, Surgery.

[5]  V. Sanders,et al.  Norepinephrine and beta 2-adrenergic receptor stimulation regulate CD4+ T and B lymphocyte function in vitro and in vivo. , 2001, Pharmacological reviews.

[6]  A. Enk,et al.  Identification and Functional Characterization of Human Cd4+Cd25+ T Cells with Regulatory Properties Isolated from Peripheral Blood , 2001, The Journal of experimental medicine.

[7]  A. Rudensky,et al.  Foxp3 programs the development and function of CD4+CD25+ regulatory T cells , 2003, Nature Immunology.

[8]  K. Madden.  Catecholamines, sympathetic innervation, and immunity , 2003, Brain, Behavior, and Immunity.

[9]  S. Ben-Eliyahu.  The promotion of tumor metastasis by surgery and stress: Immunological basis and implications for psychoneuroimmunology , 2003, Brain, Behavior, and Immunity.

[10]  G. Shakhar,et al.  Potential Prophylactic Measures Against Postoperative Immunosuppression: Could They Reduce Recurrence Rates in Oncological Patients? , 2003, Annals of Surgical Oncology.

[11]  J. Bluestone,et al.  Distinct roles of CTLA-4 and TGF-beta in CD4+CD25+ regulatory T cell function. , 2004, European journal of immunology.

[12]  J. Bluestone,et al.  Distinct roles of CTLA‐4 and TGF‐β in CD4+CD25+ regulatory T cell function , 2004 .

[13]  Geraint T. Williams,et al.  CD4+CD25+FOXP3+ Regulatory T Cells Suppress Anti-Tumor Immune Responses in Patients with Colorectal Cancer , 2006, PloS one.

[14]  A. Maung,et al.  Increased CD4+ CD25+ T Regulatory Cell Activity in Trauma Patients Depresses Protective Th1 Immunity , 2006, Annals of surgery.

[15]  S. Perez,et al.  CD4+CD25+ Regulatory T-Cell Frequency in HER-2/neu (HER)-Positive and HER-Negative Advanced-Stage Breast Cancer Patients , 2007, Clinical Cancer Research.

[16]  L. Mays,et al.  Maintaining immunological tolerance with Foxp3 , 2007, Cell Research.

[17]  D. Nance,et al.  Autonomic innervation and regulation of the immune system (1987–2007) , 2007, Brain, Behavior, and Immunity.

[18]  K. Joshi,et al.  Intratumoral FOXP3 expression in infiltrating breast carcinoma: Its association with clinicopathologic parameters and angiogenesis. , 2007, Acta oncologica.

[19]  J. Schlom,et al.  Enhanced Functionality of CD4+CD25highFoxP3+ Regulatory T Cells in the Peripheral Blood of Patients with Prostate Cancer , 2008, Clinical Cancer Research.

[20]  A. Schneeweiss,et al.  Intratumoral cytokines and tumor cell biology determine spontaneous breast cancer-specific immune responses and their correlation to prognosis. , 2009, Cancer research.

[21]  A. Sood,et al.  Surgical Stress Promotes Tumor Growth in Ovarian Carcinoma , 2009, Clinical Cancer Research.

[22]  S. Saito,et al.  Possible indications of beta-blockers in the perioperative period other than prevention of cardiac ischemia , 2010, Journal of Anesthesia.

[23]  R. Flavell,et al.  The sympathetic nervous system modulates CD4+FoxP3+ regulatory T cells via a TGF‐β‐dependent mechanism , 2009, Journal of leukocyte biology.

[24]  Min Zhang,et al.  Norepinephrine-induced invasion by pancreatic cancer cells is inhibited by propranolol. , 2009, Oncology reports.

[25]  Soldano Ferrone,et al.  A Degenerate HLA-DR Epitope Pool of HER-2/neu Reveals a Novel In vivo Immunodominant Epitope, HER-2/neu88-102 , 2010, Clinical Cancer Research.

[26]  F. Dhabhar,et al.  Short-term stress enhances cellular immunity and increases early resistance to squamous cell carcinoma , 2010, Brain, Behavior, and Immunity.

[27]  S. Sakaguchi,et al.  Regulatory T cells in tumor immunity , 2010, International journal of cancer.

[28]  I. Ellis,et al.  Beta-Blocker Drug Therapy Reduces Secondary Cancer Formation in Breast Cancer and Improves Cancer Specific Survival , 2010, Oncotarget.

[29]  M. Watanabe,et al.  Regulatory T cells and breast cancer: implications for immunopathogenesis , 2010, Cancer and Metastasis Reviews.

[30]  B. Beilin,et al.  Immune perturbations in patients along the perioperative period: Alterations in cell surface markers and leukocyte subtypes before and after surgery , 2010, Brain, Behavior, and Immunity.

[31]  L. Xiang,et al.  Immunomodulatory Effects of in vitroStress Hormones on FoxP3, Th1/Th2 Cytokine and Costimulatory Molecule mRNA Expression in Human Peripheral Blood Mononuclear Cells , 2010, Neuroimmunomodulation.

[32]  A. Sood,et al.  The sympathetic nervous system induces a metastatic switch in primary breast cancer. , 2010, Cancer research.

[33]  Liz Y. Han,et al.  Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. , 2010, The Journal of clinical investigation.

[34]  O. Zmora,et al.  Improving Survival Rates in Two Models of Spontaneous Postoperative Metastasis in Mice by Combined Administration of a β-Adrenergic Antagonist and a Cyclooxygenase-2 Inhibitor , 2010, The Journal of Immunology.

[35]  C. Bokemeyer,et al.  Decrease of CD4+FOXP3+ T regulatory cells in the peripheral blood of human subjects undergoing a mental stressor , 2010, Psychoneuroendocrinology.

[36]  I. Bartal,et al.  Synergism between immunostimulation and prevention of surgery-induced immune suppression: An approach to reduce post-operative tumor progression , 2010, Brain, Behavior, and Immunity.

[37]  K. Bennett,et al.  Beta blockers and breast cancer mortality: a population- based study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  S. Ben-Eliyahu,et al.  Improving Postoperative Immune Status and Resistance to Cancer Metastasis: A Combined Perioperative Approach of Immunostimulation and Prevention of Excessive Surgical Stress Responses , 2011, Annals of surgery.

[39]  Steven W. Cole,et al.  Molecular Pathways: Beta-Adrenergic Signaling in Cancer , 2011, Clinical Cancer Research.

[40]  Geraint T. Williams,et al.  Suppression of tumour-specific CD4+ T cells by regulatory T cells is associated with progression of human colorectal cancer , 2011, Gut.

[41]  E. Rosenne,et al.  Do Stress Responses Promote Leukemia Progression? An Animal Study Suggesting a Role for Epinephrine and Prostaglandin-E2 through Reduced NK Activity , 2011, PloS one.

[42]  O. Zmora,et al.  A New Approach to Reducing Postsurgical Cancer Recurrence: Perioperative Targeting of Catecholamines and Prostaglandins , 2012, Clinical Cancer Research.

[43]  P. Kalinski.  Regulation of Immune Responses by Prostaglandin E2 , 2012, The Journal of Immunology.

[44]  P. Marik,et al.  The immune response to surgery and trauma: Implications for treatment , 2012, The journal of trauma and acute care surgery.

[45]  S. Ben-Eliyahu,et al.  Surgery and stress promote cancer metastasis: New outlooks on perioperative mediating mechanisms and immune involvement , 2013, Brain, Behavior, and Immunity.

[46]  A. Jemal,et al.  Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.